Phase 3 Clinical Trials With Primary Completion Dates in May 2018
This is a list of Phase 3 trials with primary completion dates in May 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ALKS||Alkermes plc||2018-05-01||Phase 3||NCT02110264||Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)|
|FGEN||FibroGen, Inc||2018-05-01||Phase 3||NCT02988973||A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia|
|ICLR||ICON plc||2018-05-01||Phase 3||NCT02065882||Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency|
|KMPH||KemPharm, Inc.||2018-05-01||Phase 3||NCT03292952||KP415 Classroom Study in Children (6-12 Years of Age) With ADHD|
|PRAH||PRA Health Sciences, Inc.||2018-05-01||Phase 3||NCT02552212||Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS|
|SHPG||Shire plc||2018-05-01||Phase 3||NCT02998554||Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo|
|SHPG||Shire plc||2018-05-01||Phase 3||NCT02998541||Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo|
|SHPG||Shire plc||2018-05-01||Phase 3||NCT02093663||Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis|
|SHPG||Shire plc||2018-05-01||Phase 3||NCT02895945||BAX 802 in CHA With Inhibitors|
|SUPN||Supernus Pharmaceuticals, Inc.||2018-05-01||Phase 3||NCT02618434||Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)|
|TSRO||TESARO, Inc.||2018-05-01||Phase 3||NCT01905592||A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients|